Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults

Back to Search
Print
Bookmark Trial

NCT02725437

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
SOUSEIKAI Sumida Hospital (formerly Medical Co. LTA Sumida Hospital)
Sumida-ku, Tokyo, 130-0004, Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Clostridium Difficile Associated Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
65-85 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy male and female adults

2. Aged 65 to 85 years

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Proven or suspected prior episode of Clostridium difficile associated diarrhea


2. Unstable chronic medical condition


3. Disease requiring significant change in therapy or hospitalization for worsening
disease within 8 weeks before receipt of study vaccine


4. Serious chronic medical disorders


5. Bleeding diathesis or condition associated with prolonged bleeding time that may
contraindicate intramuscular injection


6. Any contraindication to vaccination or vaccine components, including previous
anaphylactic reaction to any vaccine or vaccine-related components


7. Subjects with congenital or acquired immunodeficiency disorders


8. Subjects with rheumatologic disorders or other illnesses requiring chronic treatment
with known immunosuppressant medications


9. Active or treated leukemia or lymphoma or bone marrow disorder


10. Residence in a nursing home or other long-term care facility, or requirement for
semiskilled nursing care or assisted living


11. Abnormality in screening hematology and/or blood chemistry laboratory values

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Clostridium Difficile Associated DiseaseEvaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
NCT01706367
  1. Pembroke Pines, Florida
  2. South Miami, Florida
  3. Overland Park, Kansas
  4. Cary, North Carolina
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Clostridium Difficile Associated DiseaseClostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
NCT03918629
  1. Phoenix, Arizona
  2. San Diego, California
  3. DeLand, Florida
  4. Raritan, New Jersey
  5. Fargo, North Dakota
  6. Little River, South Carolina
  7. Athens, Alabama
  8. Huntsville, Alabama
  9. Chandler, Arizona
  10. Peoria, Arizona
  11. Phoenix, Arizona
  12. Phoenix, Arizona
  13. Redding, California
  14. Wheat Ridge, Colorado
  15. Clearwater, Florida
  16. Miami, Florida
  17. Orlando, Florida
  18. Orlando, Florida
  19. Pembroke Pines, Florida
  20. Port Orange, Florida
  21. Savannah, Georgia
  22. Idaho Falls, Idaho
  23. Mishawaka, Indiana
  24. Metairie, Louisiana
  25. Biloxi, Mississippi
  26. Chesterfield, Missouri
  27. Rochester, New York
  28. Charlotte, North Carolina
  29. Greensboro, North Carolina
  30. Hickory, North Carolina
  31. Raleigh, North Carolina
  32. Wilmington, North Carolina
  33. Winston-Salem, North Carolina
  34. Columbus, Ohio
  35. Dayton, Ohio
  36. Goose Creek, South Carolina
  37. Mount Pleasant, South Carolina
  38. Bristol, Tennessee
  39. Austin, Texas
  40. Bellaire, Texas
  41. Fort Worth, Texas
  42. Fort Worth, Texas
  43. Houston, Texas
  44. San Antonio, Texas
  45. Tomball, Texas
  46. Tomball, Texas
  47. Draper, Utah
  48. Salt Lake City, Utah
  49. Salt Lake City, Utah
  50. South Jordan, Utah
  51. Midlothian, Virginia
  52. Wenatchee, Washington
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Clostridium Difficile Associated DiseaseEvaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
NCT03579459
  1. Mobile, Alabama
  2. Tucker, Georgia
  3. New Orleans, Louisiana
  4. Cary, North Carolina
  5. Redding, California
  6. Coral Gables, Florida
  7. DeLand, Florida
  8. Hollywood, Florida
  9. Atlanta, Georgia
  10. Stockbridge, Georgia
  11. Honolulu, Hawaii
  12. Meridian, Idaho
  13. Wichita, Kansas
  14. New Orleans, Louisiana
  15. Norfolk, Nebraska
  16. Omaha, Nebraska
  17. Raritan, New Jersey
  18. Charlotte, North Carolina
  19. Wilmington, North Carolina
  20. Oklahoma City, Oklahoma
  21. Charleston, South Carolina
  22. Austin, Texas
  23. San Antonio, Texas
  24. Draper, Utah
  25. Salt Lake City, Utah
  26. Salt Lake City, Utah
  27. South Jordan, Utah
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Clostridium Difficile Associated DiseaseA Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years
NCT02561195
  1. DeLand, Florida
  2. Hollywood, Florida
  3. South Miami, Florida
  4. Honolulu, Hawaii
  5. Overland Park, Kansas
  6. Overland Park, Kansas
  7. Omaha, Nebraska
  8. Las Vegas, Nevada
  9. Raleigh, North Carolina
  10. Wilmington, North Carolina
  11. Cincinnati, Ohio
  12. Cincinnati, Ohio
  13. Austin, Texas
  14. Houston, Texas
  15. San Antonio, Texas
  16. Salt Lake City, Utah
  17. Salt Lake City, Utah
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults
Official Title  ICMJE A Phase 1, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of Clostridium Difficile Vaccine Administered In Healthy Japanese Adults Aged 65 To 85 Years.
Brief Summary The first-in-Japanese study B5091010 has been designed to evaluate the safety, tolerability, and immunogenicity of 2 antigen dose levels of C difficile vaccine when administered as one of two 3-dose regimens to healthy Japanese adults aged 65 to 85 years.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Other
Condition  ICMJE Clostridium Difficile Associated Disease
Intervention  ICMJE
  • Biological: Clostridium difficile Vaccine
    0.5 mL intramuscular injection
  • Biological: Placebo
    0.5 mL intramuscular injection
Study Arms  ICMJE
  • Experimental: Low-dose C. difficile Vaccine (accelerated schedule)
    Intervention: Biological: Clostridium difficile Vaccine
  • Experimental: High-dose C. difficile Vaccine (accelerated schedule)
    Intervention: Biological: Clostridium difficile Vaccine
  • Placebo Comparator: Placebo (accelerated schedule)
    Intervention: Biological: Placebo
  • Experimental: Low-dose C. difficile Vaccine (non-accelerated schedule)
    Intervention: Biological: Clostridium difficile Vaccine
  • Experimental: High-dose C. difficile Vaccine (non-accelerated schedule)
    Intervention: Biological: Clostridium difficile Vaccine
  • Placebo Comparator: Placebo (non-accelerated schedule)
    Intervention: Biological: Placebo
Publications * Inoue M, Yonemura T, de Solom R, Yamaji M, Aizawa M, Knirsch C, Pride MW, Jansen KU, Gruber W, Webber C. A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults. Vaccine. 2019 May 1;37(19):2600-2607. doi: 10.1016/j.vaccine.2019.03.014. Epub 2019 Apr 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 5, 2017)		100
Original Estimated Enrollment  ICMJE
 (submitted: March 28, 2016)		128
Actual Study Completion Date  ICMJE February 2017
Actual Primary Completion Date February 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Healthy male and female adults
  2. Aged 65 to 85 years

Exclusion Criteria:

  1. Proven or suspected prior episode of Clostridium difficile associated diarrhea
  2. Unstable chronic medical condition
  3. Disease requiring significant change in therapy or hospitalization for worsening disease within 8 weeks before receipt of study vaccine
  4. Serious chronic medical disorders
  5. Bleeding diathesis or condition associated with prolonged bleeding time that may contraindicate intramuscular injection
  6. Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components
  7. Subjects with congenital or acquired immunodeficiency disorders
  8. Subjects with rheumatologic disorders or other illnesses requiring chronic treatment with known immunosuppressant medications
  9. Active or treated leukemia or lymphoma or bone marrow disorder
  10. Residence in a nursing home or other long-term care facility, or requirement for semiskilled nursing care or assisted living
  11. Abnormality in screening hematology and/or blood chemistry laboratory values
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 65 Years to 85 Years   (Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02725437
Other Study ID Numbers  ICMJE B5091010
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP